NOVT Corp. (NVTP)
OTOTC · Common · CUSIP 67010C209
Last Price•••.••
Current Yield•.••%
Yield to Call•.••%
Yield to Worst•.••%
Free registration unlocks the quote, yield calculations, price chart and full fundamentals for NVTP and every other security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Common Stock
CUSIP
67010C209
Market Cap
Small Cap · $184 Million
Previous Symbol
NOVT (changed 11/26/2007)
Previous Name
Novoste Corp.
Business: NOVT Corp., formerly Novoste Corporation, based in Atlanta GA, develops advanced medical treatments for coronary and vascular diseases and is the worldwide leader in vascular brachytherapy. The Company's Beta-Cath(TM) System is commercially available in the United States, as well as in the European Union and several other countries.
Notes: March 9, 2006, NOVT completed the sale of substantially all the assets of its vascular brachytherapy business. NOVT's trategic plan is to redeploy its existing resources to identify and acquire new business operations. NOVT's redeployment strategy will involve the acquisition of one or more operating businesses with existing or prospective taxable earnings. This strategy may allow NOVT to realize future cash flow benefits from its net operating loss carry-forwards ("NOLs"). In connection with the redeployment strategy, NOVT from time to time may review potential acquisitions, conduct due diligence, enter into letters of intent or similar agreements or otherwise evaluate potential acquisitions, and if it deems advisable, negotiate definitive acquisition agreements. No assurance can be given that the Company will find suitable candidates, and if it does, that it will be able to utilize its existing NOLs.

Company Contact

CEO
Terry Gibson
CFO
Edwin B. Cordell, Jr.
Headquarters
61 East Main Street Suite B, Los Gatos , CA 95030
Phone
408-399-6495
Investor Relations
408-399-6495
SEC EDGAR Filings
View filings »